Gerard Aurigemma to Losartan
This is a "connection" page, showing publications Gerard Aurigemma has written about Losartan.
Connection Strength
0.504
-
Aurigemma GP, Devereux RB, Wachtell K, Palmieri V, Boman K, Gerdts E, Nieminen MS, Papademetriou V, Dahl?f B. Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. Am J Hypertens. 2003 Mar; 16(3):180-6.
Score: 0.202
-
Bang CN, Gerdts E, Aurigemma GP, Boman K, Dahl?f B, Roman MJ, K?ber L, Wachtell K, Devereux RB. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens. 2013 Oct; 31(10):2060-8.
Score: 0.105
-
Chinali M, Aurigemma GP, de Simone G, Mishra RK, Gerdts E, Wachtell K, Boman K, Dahl?f B, Devereux RB. Mitral E wave deceleration time to peak E velocity ratio and cardiovascular outcome in hypertensive patients during antihypertensive treatment (from the LIFE echo-substudy). Am J Cardiol. 2009 Oct 15; 104(8):1098-104.
Score: 0.080
-
Wachtell K, Palmieri V, Olsen MH, Gerdts E, Papademetriou V, Nieminen MS, Smith G, Dahl?f B, Aurigemma GP, Devereux RB. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation. 2002 Jul 09; 106(2):227-32.
Score: 0.048
-
Bang CN, Gerdts E, Aurigemma GP, Boman K, de Simone G, Dahl?f B, K?ber L, Wachtell K, Devereux RB. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients. Circ Cardiovasc Imaging. 2014 May; 7(3):422-9.
Score: 0.027
-
Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahl?f B, Aurigemma GP, Rokkedal JE, Devereux RB. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. J Hypertens. 2010 Jul; 28(7):1541-6.
Score: 0.021
-
Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahl?f B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study. Blood Press. 2010 Jun; 19(3):169-75.
Score: 0.021